Insulin Resistance in Septic Patients in the Acute Phase and After Discharge From Hospital
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- continous blood glucose
Study Overview
Brief Summary
Surgery induces insulin resistance lasting for 2-3 weeks. We wanted to elucidate if stress-metabolic, medical conditions carry the same effect.
Detailed Description
Background: Insulin resistance is well documented after surgery in a severity positively correlated to the degree of trauma (Thorell et al. 1999; Chambrier et al. 2000). Similar phenomena have been described in severely ill patients in ICU with consequences for the survival (Van den Berghe et al. 2001; The NICE-SUGAR Study Investigators 2009). The documentation, however, is scarce and the extent is unknown in acutely ill patients with sepsis.
Method: Adult, consecutive, non-diabetic patients with elevated CRP, leukocyte counts, SOFA-score of ≥ 2 were monitored with fasting p-C-peptide, blood glucose, CRP, leukocyte count and HOMA-IR at admittance, discharge and at two follow-up visits 2 weeks and 4 weeks after admission. Blood glucose levels were measured continuously during the whole study period with a flash glucose monitor mounted on the patients' upper arm. The diagnosis was sepsis, urosepsis, pneumonia, erysipecosis, bacteremia, infection with unknow focus and covid-19.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •elevated CRP on acute asdmission
- •elevated leukocyte count on admission
- •SOFA-score ≥ 2
- •diagnosis: bacterial sepsis
- •full age and authority
Exclusion Criteria
- •not able to understand the protocol
- •not able to co-operate
- •diabetes mellitus of any kind
Outcomes
Primary Outcomes
continous blood glucose
Time Frame: 4 weeks
flash glucose monitor on the upper arm
Secondary Outcomes
- C-peptide(4 weeks)
- HOMA-IR(4 weeks)
Investigators
Jens Rikardt Andersen
Associate Professor, Primary Investigator
University of Copenhagen
